{"url_path":"/sec/mltx/8-k/2026-06-25/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1821586/0001213900-26-071721-index.html","accession_number":"0001213900-26-071721","cik":"0001821586","ticker":"MLTX","issuer_name":"MoonLake Immunotherapeutics","edgar_url":"https://www.sec.gov/Archives/edgar/data/1821586/0001213900-26-071721-index.html","primary_entity_key":"0001821586","primary_entity_name":"MoonLake Immunotherapeutics"},"word_count":110,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n \n**Description**\n\n1.1\n \n[Underwriting Agreement, dated June 23, 2026, by and between MoonLake Immunotherapeutics and Leerink Partners LLC.](ea029576601ex1-1.htm)\n\n4.1\n \n[Form of Pre-Funded Warrant](ea029576601ex4-1.htm)\n\n5.1\n \n[Opinion of Walkers (Cayman) LLP](ea029576601ex5-1.htm)\n\n23.1\n \n[Consent of Walkers (Cayman) LLP (contained in Exhibit 5.1)](ea029576601ex5-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n1\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**MOONLAKE IMMUNOTHERAPEUTICS**\n\n \n \n \n\nDate: June 25, 2026\nBy:\n/s/ Matthias Bodenstedt\n\n \nName:\nMatthias Bodenstedt\n\n \nTitle:\nChief Financial Officer\n\n \n\n2"}